Exelixis (EXEL) Earns Daily Media Sentiment Rating of 0.20

Media coverage about Exelixis (NASDAQ:EXEL) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9749819814512 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s rankings:

Shares of Exelixis (NASDAQ:EXEL) traded down $0.27 during mid-day trading on Friday, hitting $31.62. The stock had a trading volume of 2,243,300 shares, compared to its average volume of 2,430,000. The firm has a market capitalization of $9,350.00, a PE ratio of 64.53, a price-to-earnings-growth ratio of 0.95 and a beta of 1.88. Exelixis has a 12 month low of $14.90 and a 12 month high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business’s quarterly revenue was up 145.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. equities analysts expect that Exelixis will post 0.49 earnings per share for the current year.

Several equities analysts have commented on EXEL shares. Stifel Nicolaus reiterated a “hold” rating and issued a $26.00 target price on shares of Exelixis in a research report on Thursday, September 7th. Piper Jaffray Companies reiterated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Sunday, September 10th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Sunday, September 10th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of Exelixis in a research report on Tuesday, September 12th. Finally, Royal Bank of Canada started coverage on Exelixis in a research report on Thursday, September 14th. They issued an “outperform” rating and a $32.00 target price for the company. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $32.13.

TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3127742/exelixis-exel-earns-daily-media-sentiment-rating-of-0-20.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.